BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32198650)

  • 21. SWI/SNF Alterations in Squamous Bladder Cancers.
    Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
    J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers.
    Rao Q; Williamson SR; Lopez-Beltran A; Montironi R; Huang W; Eble JN; Grignon DJ; Koch MO; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Cheng L
    Mod Pathol; 2013 May; 26(5):725-32. PubMed ID: 23348900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
    Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
    Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
    Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
    Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
    Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
    Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
    Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
    Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
    Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
    J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
    Oliva E; Amin MB; Jimenez R; Young RH
    Am J Surg Pathol; 2002 Feb; 26(2):190-7. PubMed ID: 11812940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
    Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of Urachal Remnant Involvement by Urothelial Carcinoma: Intraluminal Noninvasive Spread Can Mimic a Deep-seated Bladder Invasion.
    Han L; Gallan A; Paner GP
    Am J Surg Pathol; 2019 Apr; 43(4):475-479. PubMed ID: 30475253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel.
    Tamboli P; Mohsin SK; Hailemariam S; Amin MB
    Arch Pathol Lab Med; 2002 Sep; 126(9):1057-63. PubMed ID: 12204054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
    Amin A; Murati-Amador B; Lombardo KA; Jackson CL; Grada Z; Palsgrove DN; Matoso A
    Appl Immunohistochem Mol Morphol; 2020; 28(10):786-790. PubMed ID: 31876604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Villous Morphology in Urinary Bladder Biopsy: An Approach to Diagnosis.
    Mitra S; Ayyanar P; Kaur G
    Int J Surg Pathol; 2020 Feb; 28(1):4-12. PubMed ID: 31409167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Primary adenocarcinoma of the bladder. Apropos of 5 cases].
    Lacoste MJ; Lachard A; Coulange C; Gauvin C; Rampal M
    J Urol (Paris); 1985; 91(1):37-42. PubMed ID: 4045204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.